Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 bil
MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial.
GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in tw
MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to HIBio.
Incyte and MorphoSys' antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients w
Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to buy its US rival Constellation Pharma and its pipeline of cancer and haematology therapie
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.